$1.15
Insights on Precigen Inc
Revenue is up for the last 2 quarters, 1.76M → 16.72M (in $), with an average increase of 89.4% per quarter
Netprofit is up for the last 3 quarters, -22.73M → 87.37M (in $), with an average increase of 67.6% per quarter
In the last 1 year, Seagen, Inc. has given 80.8% return, outperforming this stock by 108.5%
In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 106.2%
0.91%
Downside
Day's Volatility :9.2%
Upside
8.37%
30.0%
Downside
52 Weeks Volatility :64.85%
Upside
49.78%
Period | Precigen Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.57% | 0.0% | 0.0% |
6 Months | -12.88% | 2.2% | 0.0% |
1 Year | -27.67% | -4.7% | -2.1% |
3 Years | -85.78% | 18.0% | -6.5% |
Market Capitalization | 297.5M |
Book Value | $0.58 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.37 |
Wall Street Target Price | 9.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -1518.27% |
Return On Assets TTM | -24.26% |
Return On Equity TTM | -58.6% |
Revenue TTM | 6.8M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | -91.8% |
Gross Profit TTM | 20.6M |
EBITDA | -77.0M |
Diluted Eps TTM | -0.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.35 |
EPS Estimate Next Year | -0.31 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.07 |
What analysts predicted
Upside of 726.09%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 231.0M | ↑ 20.98% |
Net Income | -117.0M | ↓ 37.29% |
Net Profit Margin | -50.66% | ↑ 47.08% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 160.6M | ↓ 30.48% |
Net Income | -509.3M | ↑ 335.26% |
Net Profit Margin | -317.2% | ↓ 266.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 90.7M | ↓ 43.5% |
Net Income | -207.8M | ↓ 59.21% |
Net Profit Margin | -229.0% | ↑ 88.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 103.2M | ↑ 13.73% |
Net Income | -103.8M | ↓ 50.05% |
Net Profit Margin | -100.58% | ↑ 128.42% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 103.9M | ↑ 0.67% |
Net Income | -96.8M | ↓ 6.75% |
Net Profit Margin | -93.16% | ↑ 7.42% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 26.9M | ↓ 74.09% |
Net Income | -79.8M | ↓ 17.56% |
Net Profit Margin | -296.47% | ↓ 203.31% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.9M | ↓ 90.91% |
Net Income | -26.1M | ↑ 35.36% |
Net Profit Margin | -895.19% | ↓ 835.07% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 16.7M | ↑ 474.44% |
Net Income | -7.6M | ↓ 70.67% |
Net Profit Margin | -45.71% | ↑ 849.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↓ 89.46% |
Net Income | -22.2M | ↑ 190.11% |
Net Profit Margin | -1.3K% | ↓ 1212.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9M | ↑ 4.99% |
Net Income | -22.7M | ↑ 2.52% |
Net Profit Margin | -1.2K% | ↑ 29.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↓ 4.54% |
Net Income | -20.3M | ↓ 10.62% |
Net Profit Margin | -1.1K% | ↑ 78.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.7M | ↑ 846.35% |
Net Income | 87.4M | ↓ 530.04% |
Net Profit Margin | 522.54% | ↑ 1672.46% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 846.9M | ↓ 10.77% |
Total Liabilities | 300.3M | ↓ 20.93% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 716.2M | ↓ 15.43% |
Total Liabilities | 337.5M | ↑ 12.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 455.8M | ↓ 36.36% |
Total Liabilities | 384.1M | ↑ 13.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 314.6M | ↓ 30.98% |
Total Liabilities | 247.4M | ↓ 35.58% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 359.9M | ↑ 14.39% |
Total Liabilities | 252.5M | ↑ 2.06% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 216.0M | ↓ 39.98% |
Total Liabilities | 89.7M | ↓ 64.47% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 321.2M | ↓ 4.27% |
Total Liabilities | 265.6M | ↑ 1.47% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 259.2M | ↓ 19.29% |
Total Liabilities | 116.7M | ↓ 56.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 216.0M | ↓ 16.69% |
Total Liabilities | 89.7M | ↓ 23.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 241.5M | ↑ 11.84% |
Total Liabilities | 57.4M | ↓ 36.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 207.5M | ↓ 14.08% |
Total Liabilities | 41.3M | ↓ 28.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 190.7M | ↓ 8.11% |
Total Liabilities | 43.0M | ↑ 4.1% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -104.1M | ↑ 86.05% |
Investing Cash Flow | 104.3M | ↓ 467.47% |
Financing Cash Flow | 4.3M | ↓ 64.49% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.2M | ↑ 19.3% |
Investing Cash Flow | -151.2M | ↓ 244.93% |
Financing Cash Flow | 309.8M | ↑ 7131.44% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -135.9M | ↑ 9.41% |
Investing Cash Flow | 86.9M | ↓ 157.44% |
Financing Cash Flow | 8.1M | ↓ 97.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -77.0M | ↓ 43.34% |
Investing Cash Flow | 27.8M | ↓ 68.02% |
Financing Cash Flow | 32.7M | ↑ 301.88% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -55.8M | ↓ 27.59% |
Investing Cash Flow | -74.5M | ↓ 368.33% |
Financing Cash Flow | 121.2M | ↑ 270.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -65.0M | ↑ 16.63% |
Investing Cash Flow | 226.4M | ↓ 403.75% |
Financing Cash Flow | -155.3M | ↓ 228.14% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.1M | ↓ 62.45% |
Investing Cash Flow | 16.6M | ↑ 0.03% |
Financing Cash Flow | -113.0K | ↓ 30.67% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.8M | ↑ 237.63% |
Investing Cash Flow | 11.4M | ↓ 31.09% |
Financing Cash Flow | -115.7M | ↑ 102319.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.4M | ↓ 35.35% |
Investing Cash Flow | 11.4M | ↑ 0.0% |
Financing Cash Flow | -39.3M | ↓ 66.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.4M | ↑ 19.43% |
Investing Cash Flow | -50.4M | ↓ 541.36% |
Financing Cash Flow | 44.2M | ↓ 212.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.8M | ↓ 14.25% |
Investing Cash Flow | 23.5M | ↓ 146.63% |
Financing Cash Flow | -14.6M | ↓ 133.02% |
Sell
Neutral
Buy
Precigen Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Precigen Inc | -12.21% | -12.88% | -27.67% | -85.78% | -87.31% |
![]() Moderna, Inc. | 9.42% | -35.83% | -54.97% | -49.47% | 333.33% |
![]() Regeneron Pharmaceuticals, Inc. | 0.6% | 13.15% | 9.35% | 68.7% | 124.16% |
![]() Novo Nordisk A/s | -4.03% | 23.9% | 55.84% | 186.15% | 330.1% |
![]() Seagen, Inc. | 0.86% | 10.81% | 80.8% | 20.4% | 259.73% |
![]() Vertex Pharmaceuticals Incorporated | -6.55% | 8.87% | 11.3% | 55.67% | 105.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Precigen Inc | NA | NA | NA | -0.35 | -0.59 | -0.24 | 0.0 | 0.58 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Precigen Inc | Buy | $297.5M | -87.31% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $30.4B | 333.33% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 124.16% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 330.1% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 259.73% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 105.25% | 26.38 | 35.94% |
Patient Capital Management, LLC
BlackRock Inc
Vanguard Group Inc
Iridian Asset Management LLC
Geode Capital Management, LLC
State Street Corporation
Precigen Inc’s price-to-earnings ratio stands at None
Read Moreprecigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
Organization | Precigen Inc |
Employees | 209 |
CEO | Mr. Randal J. Kirk J.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$1.15
-5.74%
Advisorshares Alpha Dna Equity Sentiment Etf
$1.15
-5.74%
Falcon's Beyond Global Inc
$1.15
-5.74%
Jaguar Global Growth Corporation I
$1.15
-5.74%
Missfresh Ltd
$1.15
-5.74%
Shuaa Partners Acquisition Corp I
$1.15
-5.74%
Rose Hill Acquisition Corp
$1.15
-5.74%
Partners Bancorp
$1.15
-5.74%
Mercantile Bank Corp
$1.15
-5.74%